TORONTO, July 2 /CNW/ - Patheon (TSX:PTI), a global provider of drug
development and manufacturing services to the international pharmaceutical
industry, has completed a shareholders agreement and a sales and marketing
agreement with Italy's BSP Pharmaceuticals, a company focussed on the
development and manufacturing of cytotoxic pharmaceutical products. Under the
terms of the sales and marketing agreement, Patheon will promote BSP's
cytotoxic manufacturing capacity and development services. Mr. Aldo Braca,
President, Patheon Europe will be President and Chief Executive Officer of BSP
Pharmaceuticals. Patheon is in the process of identifying a successor to Mr.
Braca and for a transitional period, Mr. Braca will fill both roles.
